Metabolic Shifting Probiotic in Type 2 Diabetes Mellitus Management: Randomized Clinical Trial

Garcı́a, Gissel; Soto, Josanne; Rodríguez, Luis Ernesto; Nuez, Maricela; Domínguez, Noraika; Buchaca, E; Martínez, Duniesky; Gómez, Rolando J; Ávila, Yohanka; Carlin, Martha R.; Cano, Raúl J.

doi:10.26502/jbb.2642-91280090

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Here, unchanged glycemic parameters similar to baseline could indicate clinical success. This was the case in the study of García et al (2023) [21] where the probiotic subjects demonstrated stabilization of their FBG, PPG, and TC levels, while those levels in the placebo group continued to significantly increase. Similarly, the meta-analysis by Zhang et al (2022) [54] found that the reduction in fasting insulin levels became more significant with the increase in the participants' age and baseline BMI.…”

Section: Recommendations Trial Typementioning

confidence: 84%

“…Here, unchanged glycemic parameters similar to baseline could indicate clinical success. This was the case in the study of García et al (2023) [21] where the probiotic…”

Section: Glycemic Profilementioning

confidence: 92%

“…In another 3-month double-blind RCT by García et al ( 2023) [21], participants took a probiotic capsule with multiple strains or a placebo. The interest group demonstrated stabilization of their FBG, PPG and TC levels as those levels in the placebo group significantly increased.…”

Section: Biochemical Parametersmentioning

confidence: 99%

See 2 more Smart Citations

The Effects of Oral Probiotics on Type 2 Diabetes Mellitus (T2DM): A Clinical Trial Systematic Literature Review

Paquette,

Thomas,

Venkataraman

et al. 2023

Nutrients

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) remains a global health concern. Emerging clinical trial (CT) evidence suggests that probiotic intervention may promote a healthy gut microbiome in individuals with T2DM, thereby improving management of the disease. This systematic literature review summarizes thirty-three CTs investigating the use of oral probiotics for the management of T2DM. Here, twenty-one studies (64%) demonstrated an improvement in at least one glycemic parameter, while fifteen studies (45%) showed an improvement in at least one lipid parameter. However, no article in this review was able to establish a uniform decrease in glycemic, lipid, or blood pressure profiles. The lack of consistency across the studies may be attributed to differences in probiotic composition, duration of probiotic consumption, and probiotic dose. An interesting finding of this literature review was the beneficial trend of metformin and probiotic co-administration. Here, patients with T2DM taking metformin demonstrated enhanced glycemic control via the co-administration of probiotics. Taken together, the overall positive findings reported across the studies in combination with minimal adverse effects constitute ground for further quality CTs. This review provides recommendations for future CTs that may address the shortcomings of the current studies and help to extract useful data from future investigations of the use of probiotics in T2DM management.

show abstract

Section: Recommendations Trial Typementioning

confidence: 84%

“…Here, unchanged glycemic parameters similar to baseline could indicate clinical success. This was the case in the study of García et al (2023) [21] where the probiotic…”

Section: Glycemic Profilementioning

confidence: 92%